Real‐world outcomes of pembrolizumab monotherapy in non‐small cell lung cancer in Japan: A post‐marketing surveillance

This post‐marketing surveillance (PMS) was initiated in Japan to identify factors affecting the safety and effectiveness of pembrolizumab monotherapy in patients with advanced non‐small cell lung cancer (NSCLC) with programmed cell death ligand‐1 (PD‐L1) expression. This PMS was conducted from Decem...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Nobuyuki, Kamitani, Tetsu, Kanda, Kingo, Ito, Yuichiro, Hamada, Masahiro, Ozaki, Masahiko, Takeuchi, Noriko, Yamada, Tomoko, Kawano, Masaki, Maekawa, Shinichiroh, Kato, Terufumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459253/
https://www.ncbi.nlm.nih.gov/pubmed/35611470
http://dx.doi.org/10.1111/cas.15439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459253/
https://www.ncbi.nlm.nih.gov/pubmed/35611470
http://dx.doi.org/10.1111/cas.15439

Ejemplares similares